Search Results

You are looking at 1 - 10 of 74 items for :

  • Refine by Access: All content x
Clear All
Open access

Tess Jacob, Renee Garrick, and Michael D Goldberg

Background Metformin is currently recommended by many professional organizations as the first-line agent for the treatment of type 2 diabetes ( 1 ). Its multiple advantages include potent glucose-lowering efficacy, absence of weight gain

Open access

Agnieszka Łebkowska, Anna Krentowska, Agnieszka Adamska, Danuta Lipińska, Beata Piasecka, Otylia Kowal-Bielecka, Maria Górska, Robert K Semple, and Irina Kowalska

euglycaemic clamp and stabilised with a regimen of corticosteroids, hydroxychloroquine and metformin. Case presentation A 27-year-old Caucasian man with a 2-year history of psoriasis was hospitalised because of an unexplained weight loss of 20-kg in

Open access

Murray B Gordon and Kellie L Spiller

-hour 5-point mean GH: 1.7 ng/mL), which led to the acromegaly diagnosis. The patient also had an elevated baseline level of FPG (140 mg/dL) and HbA 1c (7.5%) and was being treated with metformin 1000 mg twice daily (b.i.d.), pioglitazone 45 mg once

Open access

Peter Novodvorsky, Emma Walkinshaw, Waliur Rahman, Valerie Gordon, Karen Towse, Sarah Mitchell, Dinesh Selvarajah, Priya Madhuvrata, and Alia Munir

) values were diagnostic of GDM ( 6 ) ( Table 1A ) and metformin was started at 15/40. BM values continued to be elevated on metformin ( Table 1B ), and insulin (Humulin I and Humalog (Eli Lilly)) was added 2 weeks later. Table 1 Example of capillary

Open access

N Siddique, R Durcan, S Smyth, T Kyaw Tun, S Sreenan, and J H McDermott

diagnosis of DM. Basal-bolus insulin was instituted and resulted in resolution of hyperglycaemia and osmotic symptoms. Insulin was subsequently discontinued, and he was discharged on metformin 1000 mg twice a day and gliclazide modified release of 30 mg a

Open access

Athanasios Fountas, Zoe Giotaki, Evangelia Dounousi, George Liapis, Alexandra Bargiota, Agathocles Tsatsoulis, and Stelios Tigas

cardiomyopathy ( 10 ), the patient underwent a transthoracic echocardiography and electrocardiography, which did not reveal any pathological findings. The patient was initially treated with metformin and later with pioglitazone and atorvastatin and follow

Open access

Clarissa Ern Hui Fang, Mohammed Faraz Rafey, Aine Cunningham, Sean F Dinneen, and Francis M Finucane

daily insulin dose from 35 to 18 units and added metformin 500 mg twice daily, increasing to 1000 mg 2 weeks later and gradually titrating his insulin dose to zero, 7 weeks after his initial presentation. At 6 months, his BMI, glucometer readings, HbA1c

Open access

Ken Takeshima, Hiroyuki Ariyasu, Tatsuya Ishibashi, Shintaro Kawai, Shinsuke Uraki, Jinsoo Koh, Hidefumi Ito, and Takashi Akamizu

remained uncertain. Glycemic control deteriorated over three years, with HbA1c from 7.0% to 9.4%. On admission, he was treated with 39 units of insulin aspart, sitagliptin 50 mg, voglibose 0.6 mg and metformin 1000 mg per day. The patient was suspected of

Open access

Jiman Kim, Eulsun Moon, and Seungwon Kwon

January 2012 because of several hypoglycemic events and oral hypoglycemic therapy was resumed (sitagliptin 100 mg/day, metformin 500 mg/day). However, in November 2013, diabetic nephropathy corresponding to stage 3 chronic kidney disease (CKD) was detected

Open access

Silvia M Becerra-Bayona, Víctor Alfonso Solarte-David, Claudia L Sossa, Ligia C Mateus, Martha Villamil, Jorge Pereira, and Martha L Arango-Rodríguez

arterial disease Losartan, levothyroxine sodium, atorvastatin, acetylsalicylic acid, metformin, insulin glulisine and insulin glargine 2 Chronic occlusive arterial disease and arterial hypertension Atorvastatin, acetylsalicylic acid, Losartan